Gilead Sciences (NASDAQ:GILD) Price Target Raised to $153.00

Gilead Sciences (NASDAQ:GILD) had its price objective increased by Rothschild & Co Redburn from $143.00 to $153.00 in a research note published on Monday,MarketScreener reports.

A number of other research analysts have also recently commented on the stock. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. Wolfe Research lifted their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. Finally, The Goldman Sachs Group boosted their price target on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $128.27.

Gilead Sciences Trading Up 0.7%

GILD opened at $123.40 on Monday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock’s 50 day moving average price is $116.99 and its 200-day moving average price is $112.55. Gilead Sciences has a one year low of $86.08 and a one year high of $124.87. The stock has a market cap of $153.10 billion, a price-to-earnings ratio of 24.58, a P/E/G ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts forecast that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the completion of the transaction, the insider owned 110,193 shares in the company, valued at $13,011,589.44. This trade represents a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 71,500 shares of company stock worth $8,336,040 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of institutional investors have recently modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at about $215,000. TruNorth Capital Management LLC acquired a new stake in Gilead Sciences in the first quarter worth about $70,000. Pittenger & Anderson Inc. acquired a new stake in Gilead Sciences in the first quarter worth about $65,000. Finally, LRI Investments LLC grew its stake in shares of Gilead Sciences by 65.2% during the first quarter. LRI Investments LLC now owns 1,340 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 529 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.